TED-N is under clinical development by S.Biomedics and currently in Phase II for Paralysis. According to GlobalData, Phase II drugs for Paralysis have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TED-N’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Stem cell therapy is under development for the treatment of sub-acute spinal cord injury and paralysis. It is administered through intrathecal route. It comprises of polysialic acid-neural cell adhesion molecule (PSA-NCAM)-positive neural precursor cells (NPC (PSA-NCAM positive)) derived from human embryonic stem cells.
S.Biomedics specialized in the field of stem cell therapy. It is headquartered in Seongdong, Seoul, South Korea.
For a complete picture of TED-N’s drug-specific PTSR and LoA scores, buy the report here.